Literature DB >> 34353858

Vaccination and multiple sclerosis in the era of the COVID-19 pandemic.

Tobias Monschein1, Hans-Peter Hartung1,2, Tobias Zrzavy3, Michael Barnett4, Nina Boxberger5, Thomas Berger3, Jeremy Chataway6, Amit Bar-Or7, Paulus Stefan Rommer3,5, Uwe K Zettl5.   

Abstract

Entities:  

Keywords:  COVID-19; multiple sclerosis

Year:  2021        PMID： 34353858     DOI： 10.1136/jnnp-2021-326839

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN： 0022-3050            Impact factor:   10.154


× No keyword cloud information.
  12 in total

Review 1.  An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations.

Authors:  Bulent Kantarcioglu; Omer Iqbal; Joseph Lewis; Charles A Carter; Meharvan Singh; Fabio Lievano; Mark Ligocki; Walter Jeske; Cafer Adiguzel; Grigoris T Gerotziafas; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

2.  Implementing education: Personal communication with a healthcare professional is a critical step to address vaccine hesitancy for people with multiple sclerosis.

Authors:  M G Panisset; T Kilpatrick; L E Cofré Lizama; M P Galea
Journal:  Mult Scler Relat Disord       Date:  2022-06-01       Impact factor: 4.808

3.  Vaccination Coverage against Tetanus, Diphtheria, Pertussis and Poliomyelitis and Validity of Self-Reported Vaccination Status in Patients with Multiple Sclerosis.

Authors:  Silvan Elias Langhorst; Niklas Frahm; Michael Hecker; Pegah Mashhadiakbar; Barbara Streckenbach; Julia Baldt; Felicita Heidler; Uwe Klaus Zettl
Journal:  J Pers Med       Date:  2022-04-23

Review 4.  Secondary Immunodeficiency and Risk of Infection Following Immune Therapies in Neurology.

Authors:  Fabian Szepanowski; Clemens Warnke; Gerd Meyer Zu Hörste; Anne K Mausberg; Hans-Peter Hartung; Christoph Kleinschnitz; Mark Stettner
Journal:  CNS Drugs       Date:  2021-10-16       Impact factor: 5.749

5.  Treatment patterns in pediatric patients with multiple sclerosis in Germany-a nationwide claim-based analysis.

Authors:  Niklas Frahm; Melanie Peters; Jörg Bätzing; David Ellenberger; Manas K Akmatov; Judith Haas; Paulus S Rommer; Alexander Stahmann; Uwe K Zettl; Jakob Holstiege
Journal:  Ther Adv Neurol Disord       Date:  2021-10-06       Impact factor: 6.570

6.  SARS-CoV-2 mRNA Vaccination in People with Multiple Sclerosis Treated with Fingolimod: Protective Humoral Immune Responses May Develop after the Preferred Third Shot.

Authors:  Lutz Achtnichts; Arkady Ovchinnikov; Barbara Jakopp; Michael Oberle; Krassen Nedeltchev; Christoph Andreas Fux; Johann Sellner; Oliver Findling
Journal:  Vaccines (Basel)       Date:  2022-02-21

7.  COVID-19 vaccination hesitancy among people with chronic neurological disorders: A position paper.

Authors:  Martin Rakusa; Serefnur Öztürk; Elena Moro; Raimund Helbok; Claudio L Bassetti; Ettore Beghi; Daniel Bereczki; Benedetta Bodini; Giovanni Di Liberto; Thomas M Jenkins; Antonella Macerollo; Luis F Maia; Filippo Martinelli-Boneschi; Antonio Pisani; Alberto Priori; Anna Sauerbier; Riccardo Soffietti; Pille Taba; Tim J von Oertzen; Marialuisa Zedde; Michael Crean; Anja Burlica; Francesco Cavallieri; Johann Sellner
Journal:  Eur J Neurol       Date:  2022-05-10       Impact factor: 6.288

Review 8.  Vaccination and immunotherapies in neuroimmunological diseases.

Authors:  Alexander Winkelmann; Micha Loebermann; Michael Barnett; Hans-Peter Hartung; Uwe K Zettl
Journal:  Nat Rev Neurol       Date:  2022-04-06       Impact factor: 44.711

9.  Impact of disease-modifying therapies on humoral and cellular immune-responses following SARS-CoV-2 vaccination in MS patients.

Authors:  Susan Trümpelmann; Andreas Schulte-Mecklenbeck; Olga V Steinberg; Timo Wirth; Manfred Fobker; Lisa Lohmann; Jan D Lünemann; Heinz Wiendl; Catharina C Gross; Luisa Klotz
Journal:  Clin Transl Sci       Date:  2022-03-04       Impact factor: 4.438

10.  COVID-19 Vaccination Willingness and Acceptability in Multiple Sclerosis Patients: A Cross Sectional Study in Iran.

Authors:  Seyed Massood Nabavi; Mehrnoosh Mehrabani; Leila Ghalichi; Mohammad Ali Nahayati; Mehran Ghaffari; Fereshteh Ashtari; Seyed Ehsan Mohammadianinejad; Shahedeh Karimi; Leila Faghani; Sepideh Yazdanbakhsh; Abbas Najafian; Koorosh Shahpasand; Massoud Vosough
Journal:  Vaccines (Basel)       Date:  2022-01-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.